Last reviewed · How we verify
Certican®
At a glance
| Generic name | Certican® |
|---|---|
| Also known as | Everolimus, RAD001, Myfortic, Prograf, Certican. |
| Sponsor | Novartis Pharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer (PHASE2)
- EVEROLD LONG TERM FOLLOW-UP
- De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study (PHASE3)
- Regimen Optimization Study (PHASE2)
- Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function (PHASE3)
- Mesenchymal Stromal Cell Therapy in Renal Recipients (PHASE2)
- Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation (PHASE4)
- SCHEDULE Follow Up Visit 5-7 yr (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Certican® CI brief — competitive landscape report
- Certican® updates RSS · CI watch RSS
- Novartis Pharmaceuticals portfolio CI